Key Documents
Jeffrey Norton
- Professor - Med Center Line, Surgery - General Surgery
- Member, Cancer Center
Contact Information
- Clinical Offices
Surgical Oncology 875 Blake Wilbur Dr Clinic F Stanford, CA 94305-5820 Telephone Work (650) 498-6000 Fax (650) 736-4167
- Academic Offices
Personal InformationAdministrative Contact JoAnne Smithson Administrative Assistant Email smithson@stanford.edu Tel Work (650) 498-6606Not for medical emergencies or patient use
Clinical Focus
- Adrenal Cancer
- Carcinoid Tumors
- Carcinoid Tumors - Endocrinology
- Carcinoid Tumors - Surgery
- Endocrine - Surgery
- Endocrinology Surgery
- Esophageal Cancer
- Esophageal Cancer - Thoracic Surgery
- Gastrointestinal Cancers
- Gastrointestinal Cancers - Surgical Oncology
- Gastrointestinal Oncology Surgery
- General Surgery
- Liver Cancer
- Liver Cancer - Surgery
- Multiple Endocrine Neoplasias
- Multiple Endocrine Neoplasias - Surgery
- Osteosarcoma
- Osteosarcoma - Surgery
- Pancreas Surgery
- Pancreatic Cancer
- Pancreatic Cancer - Surgery
- Parathyroid Disease
- Parathyroid Disease - Surgery
- Sarcomas - Soft Tissue
- Sarcomas - Soft Tissue - Surgery
- Sarcomas - Surgical Oncology
- Stomach Cancer
- Stomach Cancer - Surgery
- Thyroid Cancers
- Thyroid Cancers - Surgery
Department
- Cancer > GI Oncology
Professional Education
- Board Certification: General Surgery, American Board of Surgery (1983)
- Duke University Medical Center (1982) NC
- National Cancer Institute (1979) MD
- Duke University Medical Center (1974) NC
- SUNY Upstate Medical University (1973) NY
Postdoctoral Advisees
Research Interests
Interleukin-12 is a Th1 cytokine. It is important in the cell mediated immune response. We are investigating its role as an anti-tumor cytokine to augment the immune response against cancer. We are planning a human trial.
Clinical Trials
- Identification of Key Blood Molecular Markers for Immunotherapy Recruiting
- Evaluation of Preexisiting Immunity Markers in Human Tumor Tissue Sample No longer recruiting
- Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer Completed
- Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx Completed
- Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer No longer recruiting
- Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer No longer recruiting
- Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer Completed
Publications
- Surg Clin North Am. 2009; (5): 1091-103
- Endocr Pract. 2009; 1-22
- Sarcoma. 2009; 605840
- Arch Surg. 2009; (9): 817-22
- Am J Surg Pathol. 2009;
- Dig Dis Sci. 2009;
- Clin Oncol (R Coll Radiol). 2008; (1): 69-75
- Cancer. 2008; (7 Suppl): 1850-6
- Future Oncol. 2008; (4): 553-9
- Ann Surg. 2008; (4): 715-716
- Am J Surg Pathol. 2008; (6): 799-809
- Int J Radiat Oncol Biol Phys. 2008; (4): 1146-53
- Int J Radiat Oncol Biol Phys. 2008; (3): 678-86
- Ann Surg. 2008; (3): 501-10
- Ann Surg. 2008; (4): 715-6
- Ann Surg. 2007; (6): 873-9
- Adv Surg. 2007; 165-76
- J Am Coll Surg. 2007; (4 Suppl): S34-7
- Ann Surg. 2006; (3): 410-9
- Ann Surg Oncol. 2006; (1): 118-24
- J Natl Compr Canc Netw. 2006; (2): 148-53
- J Gastrointest Surg. 2006; (3): 327-31
- Surg Oncol. 2006; (1): 25-8
- J Gastrointest Surg. 2005; (1): 15-20; discussion 20-1
- Best Pract Res Clin Gastroenterol. 2005; (4): 577-83
- Surg Oncol. 2005; (2): 105-13
- Int J Radiat Oncol Biol Phys. 2005; (2): 320-3
- Best Pract Res Clin Gastroenterol. 2005; (5): 799-805
- Best Pract Res Clin Gastroenterol. 2005; (5): 699-704
- Surgery. 2004; (6): 1267-74
- Ann Surg. 2004; (5): 617-25; discussion 626
- Ann Surg. 2004; (5): 757-73
- Science. 2001; (5507): 1298-302